Clinical-stage company developing unique bifunctional antibodies targeting tumors and modulating their microenvironment for treating cancer.
Bicara Therapeutics
Oncology
Total Addressable Market
Red Tree Board Member(s)
Red Tree Board Member
Krishna Polu, M.D.
Red Tree Board Observer
Jon Edwards, Ph.D.
Red Tree Participation
Co-investor in seed round
